An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib.
Authors
Mateo, JMoreno, V
Gupta, A
Kaye, S
Dean, Emma J
Middleton, M
Friedlander, M
Gourley, C
Plummer, R
Rustin, G
Sessa, C
Leunen, K
Ledermann, J
Swaisland, H
Fielding, A
Bannister, W
Nicum, S
Molife, L
Affiliation
Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Downs Road, Sutton, SM2 5PT, UKIssue Date
2016-06
Metadata
Show full item recordAbstract
Olaparib is poorly soluble, requiring advanced drug delivery technologies for adequate bioavailability. Sixteen capsules/day are required for the approved 400 mg twice-daily dose; a tablet formulation was developed to reduce pill burden. This clinical trial evaluated the optimal dose and administration schedule of the tablet formulation.Citation
An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. 2016, 11 (3):401-15 Target OncolJournal
Targeted OncologyDOI
10.1007/s11523-016-0435-8PubMed ID
27169564Type
ArticleLanguage
enISSN
1776-260Xae974a485f413a2113503eed53cd6c53
10.1007/s11523-016-0435-8